1. Rubboli G, Tassinari CA. Negative myoclonus. An overview of its clinical features, pathophysiological mechanisms, and management. Neurophysiol Clin. 2006; 36:337–43.
2. Eberhardt O, Topka H. Myoclonic disorders. Brain Sci. 2017; 7:pii: E103.
Article
3. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia. 2001; 42:790–2.
Article
4. Heckmann JG, Ulrich K, Dütsch M, Neundörfer B. Pregabalin associated asterixis. Am J Phys Med Rehabil. 2005; 84:724.
Article
5. Knake S, Klein KM, Hattemer K, Wellek A, Oertel WH, Hamer HM, et al. Pregabalin-induced generalized myoclonic status epilepticus in patients with chronic pain. Epilepsy Behav. 2007; 11:471–3.
Article
6. Hellwig S, Amtage F. Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain. Epilepsy Behav. 2008; 13:418–20.
Article
7. Kim JB, Jung JM, Park MH, Lee EJ, Kwon DY. Negative myoclonus induced by gabapentin and pregabalin: a case series and systematic literature review. J Neurol Sci. 2017; 382:36–9.
Article
8. Healy DG, Ingle GT, Brown P. Pregabalin- and gabapentinassociated myoclonus in a patient with chronic renal failure. Mov Disord. 2009; 24:2028–9.
Article
9. Brefel-Courbon C, Gardette V, Ory F, Montastruc JL. Druginduced myoclonus: a French pharmacovigilance database study. Neurophysiol Clin. 2006; 36:333–6.
10. Rao ML, Clarenbach P, Vahlensieck M, Krätzschmar S. Gabapentin augments whole blood serotonin in healthy young men. J Neural Transm. 1988; 73:129–34.
Article
11. Pappert EJ, Goetz CG, Stebbins GT, Belden M, Carvey PM. 5-Hydroxytryptophan-induced myoclonus in guinea pigs: mediation through 5-HT1/2 receptor subtypes. Eur J Pharmacol. 1998; 347:51–6.
Article
12. Asconapé J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia. 2000; 41:479–81.
Article